Because of the reported biological activities of coumarin, 1,3,4-oxadiazole, and acetamides, some new compounds incorporating these moieties were synthesized and evaluated for their biological potential against Gram-positive and Gram-negative bacteria. In the present work, 4-chlororesorcinol (1) and ethyl acetoacetate (2) were mixed in a strong acidic medium to synthesize 6-chloro-7-hydroxy-4-methyl-2-oxo-2H-chromene (3) which was subjected to the intermolecular cyclization after consecutive three steps to synthesize 5-{[(6-chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]methyl}-1,3,4-oxadiazol-2-thiol (6). A series of acetamoyl electrophiles, 8a-o, were synthesized from aralkyl/alkyl/aryl amines, 7a-o, in an aqueous basic medium. The final compounds, 9a-o, were synthesized by the reaction of compounds 6 and 8a-o in DMF/NaH. The synthesized compounds were structurally elucidated by spectral data analysis of IR, 1 H-NMR, and EIMS. The most of the synthesized compounds remained moderate to excellent antibacterial agents. The molecules, 9e, 9j, and 9k, were the most efficient ones against all the five bacterial strains taken into account.
Introduction
Coumarin is a naturally occurring heterocyclic class of compounds [1] [2] [3] . The compounds of this class were used by ancient Egyptians as drug [4] . The field of agriculture has also found the applications of these molecules [4, 5] . The different derivatives of various coumarins have been introduced synthetically and also by plant extraction to possess a number of biological activities including antibacterial, antioxidant, and anti-inflammatory activities [6] [7] [8] [9] . The heterocyclic moiety, 1,3,4-oxadiazole, and its various 2,5-disubstituted products are also known to be biologically active compounds [10] [11] [12] .
The presence of amide functionality is also known to boost up the potential of bioactive compounds including antifungal, anti-inflammatory, anticancer, antibacterial, and antioxidant activities [13] [14] [15] [16] .
The increased resistance by microbes against the existing drugs is the key point for search of new drug molecules [17, 18] . In continuation of our previous work on O-substituted derivatives [19] and notable bioactivity of ether derivatives of coumarin [6, 9, 20] this prompted us to incorporate coumarin with 1,3,4-oxadiazole and acetamides to evaluate their antibacterial activity. 
Experimental

Material and Methods.
4-Chlororesorcinol, ethyl acetoacetate, ethyl 2-bromoacetate, hydrated hydrazine, carbon disulfide, aralkyl/alkyl/aryl amines, and 2-bromoacetyl bromide were purchased from Merck, Riedel-de Haen, Aldrich, and Alfa Aesar through local suppliers along with analytical grade solvents. The Jasco-320-A spectrophotometer was used to record IR spectra by KBr pellet method. The Bruker spectrometers at 125 and 400 MHz were used to record the 13 C and 1 H NMR spectra in CDCl 3 , respectively. The JMS-HX-110 spectrometer was used to record EIMS spectra. Silica plates coated on alumina were used for thin layer chromatography (TLC), run in mobile phase of n-hexane and ethyl acetate and observed under UV 254 . Griffin-George apparatus was used to record the melting points in open capillary tubes which were uncorrected.
Synthesis of 6-Chloro-7-hydroxy-4-methyl-2-oxo-2H-chromene (3)
. 4-Chlororesorcinol (0.05 mol; 1) was dissolved in ethyl acetoacetate (0.05 mol; 2) on heating in an iodine flask (500 mL). Then concentrated H 2 SO 4 (25 mL) was added on continuous shaking at low temperature. The mixture was aged for 12-16 hours. Excess cold distilled water was added to precipitate the title compound which was separated through filtration, washed by distilled water, and dried. (4) . Compound 3 (0.045 mol) was dissolved in DMF (25 mL) in a round bottom (RB) flask (250 mL) and then NaH (0.045 mol) was added. The mixture was stirred for 0.5 hours and then ethyl 2-bromoacetate (0.045 mol) was added. The stirring was continued for 3-4 hours along with monitoring through TLC. Excess cold distilled water was added and the formed precipitates were filtered out, washed, and dried. (5) . The ethyl ester 4 (0.04 mol) was mixed with methanol (35 mL) in a RB flask (250 mL). The hydrated hydrazine (0.04 mol) was added and the mixture was set to stir for 2-3 hours. TLC was frequently developed to monitor the reaction. Solvent was evaporated to one-third and then excess of distilled water was added to precipitate the product. The precipitates were acquired through filtration and subjected to washing and drying. (6) . Compound 5 (0.035 mol) was added to absolute ethanol (50 mL) in a RB flask (250 mL) followed by solid KOH (0.035 mol). The mixture was homogenized on reflux and then cooled to room temperature and liquid CS 2 (0.07 mol) was added. The mixture was again set to reflux for 4-5 hours along with supervision by TLC. Solvent was evaporated to one-third and then excess cold distilled water was added. The pH of this homogeneous solution was adjusted to 6-7 by dilute HCl and aged for 0.5 hours to allow maximum precipitation. The precipitates were filtered, washed with distilled water, and dried.
Synthesis of Ethyl 2-[(6-Chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]acetate
Synthesis of 2-[(6-Chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]acetohydrazide
Synthesis of 5-{[(6-Chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]methyl}-1,3,4-oxadiazol-2-thiol
General Synthesis of N-Aralkyl/alkyl/aryl-2-bromoacetamide (8a-o).
Aralkyl/alkyl/aryl amines (0.005 mol; 7a-o) were dispersed in distilled water (15 mL) in an iodine flask (125 mL). The pH was adjusted to 8-9 by aqueous Na 2 CO 3 solution (15%, 4 mL). Then 2-bromoacetyl bromide (0.005 mol) was added on vigorous stirring and further set to stir for 1 hour on maintained pH. The precipitates of title products were filtered off, washed by distilled water and dried.
General Synthesis of N-
Compound 6 (0.002 mol) was dissolved in DMF (12 mL) in a round bottom flask (50 mL) followed by NaH (0.002 mol). The mixture was stirred for 0.5 hours and then N-aralkyl/alkyl/aryl-2-bromoacetamide (0.002 mol; 8a-o) were added. The stirring was continued for 4-6 hours along with monitoring through TLC. Excess cold distilled water was added and the precipitates were filtered out, washed, and dried. [21, 22] . The change in absorbance before and after the addition of sample compound was noted. The absorbance is varied with number of microbial cells which are varied with log phase microbial growth.
The clinically isolated three Gram-negative and two Gram-positive bacteria were stored on stock culture agar medium. A mixture of 200 L was prepared by 180 L fresh nutrient broth with suitable dilutions and 20 g test samples with suitable dilutions. All the dilutions were performed using specific suited solvents. Before and after incubation at 37 ∘ C for 16-24 hrs with lid on the microplate, the absorbance (0.12-0.19 at beginning) was measured at 540 nm. The variation in absorbance was the criteria for bacterial growth. The percent inhibition was calculated by the following formula:
where is absorbance in control with bacterial culture and is absorbance in test sample. •+ (17%), 193 (7%), 182 (5%), 175 (BP, 100%), 165 (3%), 149 (2%), 134 (5%). •+ (16%), 289 (14%), 251 (3%), 249 (7%), 230 (2%), 214 (13%), 210 (86%), 193 (13%), 182 (BP, 100%), 165 (7%), 149 (4%), 134 (16%). 20 (s, 1H, H-3 ), 5.34 (s, 2H, H-12 ), 3.98 (s,  2H, H-2 •+ (20%), 500 (14%), 251 (6%), 249 (8%), 230 (4%), 214 (13%), 210 (92%), 198 (33%), 193 (13%), 182 (BP, 100%), 170 (31%), 165 (6%), 149 (8%), 134 (11%). 
Ethyl 2-[(6-Chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]acetate (4)
.
2-[(6-Chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]acetohydrazide (5)
5-{[(6-Chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]methyl}-1,3,4-oxadiazol-2-thiol (6)
N-Cyclohexyl-2-[(5-{[(6-chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]methyl}-1,3,4-oxadiazol-2-yl)sulfanyl]acetamide (9a
N-(2-Phenylethyl)-2-[(5-{[(6-chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]methyl}-1,3,4-oxadiazol-2-yl)sulfanyl]acetamide (9c
N-Phenyl-2-[(5-{[(6-chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]methyl}-1,3,4-oxadiazol-2-yl)sulfanyl]acetamide (9d
N-(4-Methylphenyl)-2-[(5-{[(6-chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]methyl}-1,3,4-oxadiazol-2-yl)sulfanyl]acetamide (9g
N-(2-Ethylphenyl)-2-[(5-{[(6-chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]methyl}-1,3,4-oxadiazol-2-yl)sulfanyl]acetamide (9h
N-(4-Ethylphenyl)-2-[(5-{[(6-chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]methyl}-1,3,4-oxadiazol-2-yl)sulfanyl]acetamide (9i)
N-(2-Methoxyphenyl)-2-[(5-{[(6-chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]methyl}-1,3,4-oxadiazol-2-yl)sulfanyl]acetamide (9j
N-(2-Ethoxyphenyl)-2-[(5-{[(6-chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]methyl}-1,3,4-oxadiazol-2-yl)sulfanyl]acetamide (9k)
N-(4-Ethoxyphenyl)-2-[(5-{[(6-chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]methyl}-1,3,4-oxadiazol-2-yl)sulfanyl]acetamide (9l
N-(2-Methoxycarbonylphenyl)-2-[(5-{[(6-chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]methyl}-1,3,4-oxadiazol-2-yl)sulfanyl]acetamide (9m)
N-(4-Bromophenyl)-2-[(5-{[(6-chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]methyl}-1,3,4-oxadiazol-2-yl)sulfanyl]acetamide (9n)
N-(4-Nitrophenyl)-2-[(5-{[(6-chloro-4-methyl-2-oxo-2H-chromen-7-yl)oxy]methyl}-1,3,4-oxadiazol-2-yl)sulfanyl]acetamide (9o
Results and Discussion
The different N-aralkyl/alkyl/aryl acetamides incorporating coumarin and 1,3,4-oxadiazole rings, 9a-o, were synthesized by the multistep protocol given in Scheme 1. The synthesis was aimed at combining multiple functionalities in a single molecule so these may be able to demonstrate more efficient biological activity. The antibacterial behavior of these molecules was tested against Gram-bacteria including positive and negative strains. The three negative and two positive bacterial strains have been reported to be the cause of various diseases [23] [24] [25] [26] [27] .
3.1. Chemistry. First 4-chlororesorcinol (1) was treated with ethyl acetoacetate (2) in a strong acidic medium to yield 6-chloro-7-hydroxy-4-methyl-2H-chromen-2-one (3) which was separated through filtration. Compound 3 was further O-substituted by ethyl 2-bromoacetate in a polar aprotic solvent with the aid of a weak base. This substituted ester, 4, was converted to corresponding carbohydrazide, 5, after a simple nucleophilic substitution reaction by hydrazine in methanol. The carbohydrazide was cyclized to 5-substituted-1,3,4-oxadiazol-2-thiol by CS 2 in an alcoholic KOH medium on reflux. A list of electrophiles, 8a-o, was synthesized from different aralkyl/alkyl/aryl amines, 7a-o, on simple stirring with 2-bromoacetyl bromide in aqueous Na 2 CO 3 medium. The final compounds were geared up by stirring 6 with 8a-o again in DMF in the presence of NaH and separated through filtration after addition of excess distilled water.
All the compounds were structurally corroborated through IR, 1 H-NMR, and EIMS spectral data. Compound 3 is also aided by 13 C-NMR data. One molecule description is given for 9h. Its molecular formula was nominated as C 23 H 20 ClN 3 O 5 S, elucidated with the aid of molecular ion peak in EIMS spectrum and integration of protons in 1 H-NMR spectrum. The suggested fragmentation pattern of this molecule is also sketched in Figure 1 
Antibacterial Activity (In Vitro).
The results of antibacterial activity evaluation against Gram-bacteria were presented as percentage of age inhibition and MIC values in Tables 1  and 2 . The ciprofloxacin was used as reference standard. All the compounds demonstrated moderate to excellent activity except a few. The Gram-negative strain, S. typhi, was not inhibited by 9b and 9d. It was the most efficiently inhibited by 9e, 9f, 9h, 9j, 9k, and 9m. The best activity against it was observed for 9j with MIC value of 8.87 ± 1.20 g/mL and 9k as 8.84 ± 2.00 g/mL with respect to that of reference as 8.00 ± 2.54 g/mL. Only 9o was inactive against E. coli and remaining moderate to good with the efficient ones as 9e, 9f, 9j, 9k, and 9m. The most active one was 9f with MIC of 10.15 ± 4.12 relative to 7.96 ± 1.14 g/mL. Against P. aeruginosa, 9b and 9o were inactive and remaining weakly moderate. The efficient ones against this strain were 9a, 9c, 9e, 9f, 9h, 9j, and 9m. It was most actively inhibited by 9e presenting MIC of 10.22 ± 3.33 g/mL as compared to 8.05 ± 1.60 g/mL. B. subtilis was moderately inhibited by all the molecules and efficiently by 9n with MIC of 11.95 ± 4.71 g/mL in comparison with 8.32 ± 1.00 g/mL.
The compounds against S. aureus were moderate to excellent inhibitors including 9c, 9e, 9j, 9k, and 9l. The molecule 9e was the most efficient with MIC of 8.90 ± 2.08 g/mL relative to 7.43 ± 0.45 g/mL. The three compounds 9d, 9i, and 9n were inactive at all against this strain. Overall the Gramnegative strains were efficiently inhibited by the synthesized molecules relative to Gram-positive ones. The best activity
